Miri, Seyed Rouhollah
Mayo Clinic
Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Science, Tehran, Iran.
Citations 2
Anticoagulant therapy in COVID ‐19: A narrative review
Afshar, Zeinab Mohseni , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Moghadam, Mohamad Ali Taghizadeh, Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Barary, Mohammad , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Tavakoli Pirzaman, Ali , Babazadeh, Arefeh , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Barary, Mohammad , Ebrahimpour, Soheil
Clinical and Translational Science | June 16, 2023 | Volume: 16 | Issue: 9 | Pages: 1510-1525
Abstract Coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), can manifest itself in several ways, including coagulopathy and thrombosis. These complications can be the first and sometimes only manifestations of SARS‐CoV‐2 infection and can occur early or late in the course of the disease. However, these symptoms are more prevalent in hospitalized patients with venous thromboembolism, particularly those admitted to intensive care units. Moreover, various forms of arterial and venous thrombosis, or micro‐ or macro‐vasculature embolisms, have been reported during the current pandemic. They have led to harmful consequences, such as neurological and cardiac events, nearly all resulting from the hypercoagulable state caused by this viral infection. The severe hypercoagulability observed in patients with COVID‐19 accounts for most cases of the disease that become critical. Therefore, anticoagulants seem to be one of the most vital therapeutics for treating this potentially life‐threatening condition. In the current paper, we present a thorough review of the pathophysiology of COVID‐19‐induced hypercoagulable state and the use of anticoagulants to treat SARS‐CoV‐2 infections in different patient groups, as well as their pros and cons.
The role of cytokines and their antagonists in the treatment of COVID‐19 patients
Afshar, Zeinab Mohseni , Barary, Mohammad , Pirzaman, Ali Tavakoli , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T. , Sullman, Mark J. M. , Carson‐Chahhoud, Kristin , Ebrahimpour, Soheil , Mohseni Afshar, Zeinab , Babazadeh, Arefeh , Tavakoli Pirzaman, Ali , Hosseinzadeh, Rezvan , Alijanpour, Amirmasoud , Allahgholipour, Amirreza , Miri, Seyed Rouhollah , Sio, Terence T , Sullman, Mark J M , Carson-Chahhoud, Kristin , Ebrahimpour, Soheil , Barary, Mohammad
Reviews in Medical Virology | May 27, 2022 | Volume: 33 | Issue: 1 | Pages: No page available
AbstractThe coronavirus disease 2019 (COVID‐19) has various presentations, of which immune dysregulation or the so‐called cytokine storm syndrome (COVID‐CSS) is prominent. Even though cytokines are vital regulators of body immunoinflammatory responses, their exaggerated release can be harmful. This hyperinflammatory response is more commonly observed during severe COVID‐19 infections, caused by the excessive release of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, IL‐8, tumour necrosis factor, granulocyte‐macrophage colony‐stimulating factor, and interferon‐gamma, making their blockers and antagonists of great interest as therapeutic options in this condition. Thus, the pathophysiology of excessive cytokine secretion is outlined, and their most important blockers and antagonists are discussed, mainly focussing on tocilizumab, an interleukin‐6 receptor blocker approved to treat severe COVID‐19 infections.